AML
News
Global burden of hematologic malignancies
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
News
Study could change treatment of MLSM7
New findings could help improve treatment of an inherited bone marrow disorder known as myelodysplasia and leukemia syndrome with monosomy 7 (...
News
Treatments, disease affect spermatogonia in boys
Alkylating agents, hydroxyurea (HU), and certain non-malignant diseases can significantly deplete spermatogonial cell counts in young boys,...
News
FDA approves drug for IDH1-mutated AML
The US Food and Drug Administration (FDA) has granted full approval for the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (Tibsovo®)....
News
FDA approves biosimilar filgrastim
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (...
News
FDA approves Nivestym, second biosimilar to Neupogen
Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the FDA.
News
FDA approves IDH1 inhibitor for relapsed/refractory AML
The oral medication is the first and only FDA-approved treatment for relapsed/refractory AML with an IDH1 mutation.
News
Diabetics have higher risk of hematologic, other cancers
A review of data from more than 19 million people indicates that diabetes significantly raises a person’s risk of developing cancer. When...
News
Study suggests dasatinib could treat AML, JMML
New research suggests dasatinib could treat certain patients with juvenile myelomonocytic leukemia (JMML) or acute myeloid leukemia (AML). The...
News
Explaining enasidenib resistance in AML
New research helps explain enasidenib resistance among patients with IDH2-mutant acute myeloid leukemia (AML). Researchers found that leukemic...